Evidence map›Paper›PMID 24449420›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2014

Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts.

Huamei He, Hai Tao, Hui Xiong, Sheng Zhong Duan, Francis X McGowan, Richard M Mortensen, James A Balschi

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Animal cells and systems · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity.Frontiers in cell and developmental biology · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Huamei HeDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Hai Tao
Hui Xiong
Sheng Zhong Duan
Francis X McGowan
Richard M Mortensen
James A Balschi
Brigham and Women's Hospital · USChildren's Hospital of Philadelphia · USHarvard University · USShanghai Institutes for Biological Sciences · CNUniversity of Michigan–Ann Arbor · USUniversity of Pennsylvania · US

Funding

SSCOR in Pediatric Heart Development and DiseaseP50HL074734 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI COLLINS, TUCKER O · 2004 to 2008
$19.9M
Causes and consequences of AMPK activation in the heartR01HL046033 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BALSCHI, JAMES ALVIN · 1998 to 2005
$1.9M
Myeloid Reprogramming in Cardiac Protection by Aldosterone AntagonistsR01HL112610 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORTENSEN, RICHARD M · 2014 to 2017
$1.6M
Metabolic responsive factors in cardiovascular diseaseR01HL083201 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORTENSEN, RICHARD M · 2006 to 2009
$1.5M
New MR methods to measure myocardial intracelluler [Na+]R01HL078634 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BALSCHI, JAMES ALVIN · 2004 to 2007
$1.5M
NHLBI NIH HHS HL78634NHLBI NIH HHS P50 HL074734NHLBI NIH HHS R01 HL083201NHLBI NIH HHS R01 HL112610NHLBI NIH HHS R01 HL46033
6 · The paper itself

Abstract

This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor γ (PPARγ) agonist, causes cardiotoxicity independently of PPARγ. Energy metabolism and mitochondrial function were measured in perfused hearts isolated from C57BL/6, cardiomyocyte-specific PPARγ-deficient mice, and their littermates. Cardiac function and mitochondrial oxidative stress were measured in both in vitro and in vivo settings. Treatment of isolated hearts with RSG at the supratherapeutic concentrations of 10 and 30 μM caused myocardial energy deficiency as evidenced by the decreases in [PCr], [ATP], ATP/ADP ratio, energy charge with a concomitant cardiac dysfunction as indicated by the decreases in left ventricular systolic pressure, rates of tension development and relaxation, and by an increase in end-diastolic pressure. When incubated with tissue homogenate or isolated mitochondria at these same concentrations, RSG caused mitochondrial dysfunction as evidenced by the decreases in respiration rate, substrate oxidation rates, and activities of complexes I and IV. RSG also increased complexes I- and III-dependent O₂⁻ production, decreased glutathione content, inhibited superoxide dismutase, and increased the levels of malondialdehyde, protein carbonyl, and 8-hydroxy-2-deoxyguanosine in mitochondria, consistent with oxidative stress. N-acetyl-L-cysteine (NAC) 20 mM prevented RSG-induced above toxicity at those in vitro settings. Cardiomyocyte-specific PPARγ deletion and PPARγ antagonist GW9662 did not prevent the observed cardiotoxicity. Intravenous injection of 10 mg/kg RSG also caused cardiac dysfunction and oxidative stress, 600 mg/kg NAC antagonized these adverse effects. In conclusion, this study demonstrates that RSG at supratherapeutic concentrations causes cardiotoxicity via a PPARγ-independent mechanism involving oxidative stress-induced mitochondrial dysfunction in mouse hearts.

Indexed as

AnilidesAnimalsCardiotoxinsDose-Response Relationship, DrugEnergy MetabolismHeartHeart Function TestsIn Vitro TechniquesMaleMiceMice, Inbred C57BLMice, KnockoutMitochondria, HeartOxidative StressPerfusionPPAR gamma2-chloro-5-nitrobenzanilideAnilidesCardiotoxinsPPAR gammaRosiglitazoneThiazolidinedionescardiac functionenergy metabolismmitochondriaoxidative stressPPARγRosiglitazone

Identifiers

PMID24449420
PMCPMC4243497
OpenAlexW2104516245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.